Schizophrenia Bulletin Advance Access originally published online on March 15, 2006
Schizophrenia Bulletin 2006 32(4):715-723; doi:10.1093/schbul/sbj067
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia
2 University of Manchester
3 Imperial College, London
4 Institute of Psychiatry, London
5 University of Cambridge
1To whom correspondence should be addressed; e-mail: shon.lewis{at}manchester.ac.uk
There is good evidence that clozapine is more efficacious than first-generation antipsychotic drugs in resistant schizophrenia. It is less clear if clozapine is more effective than the other second-generation antipsychotic (SGA) drugs. A noncommercially funded, pragmatic, open, multisite, randomized controlled trial was conducted in the United Kingdom National Health Service (NHS). Participants were 136 people aged 18–65 with DSM-IV schizophrenia and related disorders whose medication was being changed because of poor clinical response to 2 or more previous antipsychotic drugs. Participants were randomly allocated to clozapine or to one of the class of other SGA drugs (risperidone, olanzapine, quetiapine, amisulpride) as selected by the managing clinician. Outcomes were assessed blind to treatment allocation. One-year assessments were carried out in 87% of the sample. The intent to treat comparison showed no statistically significant advantage for commencing clozapine in Quality of Life score (3.63 points; CI: 0.46–7.71; p = .08) but did show an advantage in Positive and Negative Syndrome Scale (PANSS) total score that was statistically significant (–4.93 points; CI: –8.82 to –1.05; p = .013) during follow-up. Clozapine showed a trend toward having fewer total extrapyramidal side effects. At 12 weeks participants who were receiving clozapine reported that their mental health was significantly better compared with those receiving other SGA drugs. In conclusion, in people with schizophrenia with poor treatment response to 2 or more antipsychotic drugs, there is an advantage to commencing clozapine rather than other SGA drugs in terms of symptom improvement over 1 year.
Keywords: schizophrenia / clozapine / quality of life / clinical trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials Schizophr Bull, March 1, 2009; 35(2): 443 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Wheeler Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand Ann. Pharmacother., June 1, 2008; 42(6): 852 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Carpenter and R. W. Buchanan Lessons to Take Home From CATIE Psychiatr Serv, May 1, 2008; 59(5): 523 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment Schizophr Bull, April 2, 2008; (2008) sbn019v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kane and S. Leucht Unanswered Questions in Schizophrenia Clinical Trials Schizophr Bull, March 1, 2008; 34(2): 302 - 309. [Full Text] [PDF]
|
|
|
|
|
|
T. S. Stroup and J. R. Geddes Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals Schizophr Bull, March 1, 2008; 34(2): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lewis and J. Lieberman CATIE and CUtLASS: can we handle the truth? The British Journal of Psychiatry, March 1, 2008; 192(3): 161 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia J Psychopharmacol, June 1, 2007; 21(4): 357 - 373. [Abstract] [PDF]
|
|
|
|
 |
|
 R. E McCue Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia Evid. Based Ment. Health, May 1, 2007; 10(2): 57 - 57. [Full Text] [PDF]
|
|
|
|
 |
|
 N. B. Sandson, K. L. Cozza, S. C. Armstrong, G. Eckermann, B. A. Fischer, and B. Phillips Clozapine Case Series Psychosomatics, April 1, 2007; 48(2): 170 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. ADAMS, P. THARYAN, E. S. F. COUTINHO, and T. S. STROUP The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries The British Journal of Psychiatry, November 1, 2006; 189(5): 391 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Lieberman Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry, October 1, 2006; 63(10): 1069 - 1072. [Full Text] [PDF]
|
|